Growth Metrics

Innoviva (INVA) EPS (Weighted Average and Diluted) (2016 - 2025)

Innoviva's EPS (Weighted Average and Diluted) history spans 15 years, with the latest figure at $1.08 for Q3 2025.

  • For Q3 2025, EPS (Weighted Average and Diluted) rose 5300.0% year-over-year to $1.08; the TTM value through Sep 2025 reached $1.13, up 24.18%, while the annual FY2025 figure was $3.3, 816.67% up from the prior year.
  • EPS (Weighted Average and Diluted) reached $1.08 in Q3 2025 per INVA's latest filing, up from $0.77 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $2.8 in Q3 2022 to a low of -$0.74 in Q1 2025.
  • Average EPS (Weighted Average and Diluted) over 5 years is $0.54, with a median of $0.46 recorded in 2024.
  • Peak YoY movement for EPS (Weighted Average and Diluted): crashed 2850.0% in 2024, then surged 5300.0% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.9 in 2021, then surged by 211.11% to $2.8 in 2022, then tumbled by 65.0% to $0.98 in 2023, then tumbled by 97.96% to $0.02 in 2024, then soared by 5300.0% to $1.08 in 2025.
  • Per Business Quant, the three most recent readings for INVA's EPS (Weighted Average and Diluted) are $1.08 (Q3 2025), $0.77 (Q2 2025), and -$0.74 (Q1 2025).